EC Microbiology

Introduction: Despite covid 19 principally affecting the respiratory system, other biological systems such as the nervous system also get affected. Encephalitis is an inflammatory condition of the brain with significant morbidity and mortality rates. Encephalitis is almost always caused by a viral infection. The common symptoms of encephalitis include headache, fever, vomiting, convulsions, focal neurological deficits, and consciousness disorders. Diagnosis is mainly due to the PCR test of the cerebrospinal fluid. Management of encephalitis includes supportive care, antivirals, and steroids.

Aim of the Work: An overview is aimed at describing encephalitis post covid 19 infection and its management.

Methodology: The review is a thorough review of PUBMED articles from the year 1997 to 2021 relating to encephalitis post covid 19.

Conclusion: Since the advent of coronavirus infection by SAR CoV 2 in Wuhan, China, we have witnessed millions of cases across the world in a global pandemic. Many lives have been lost, and the disease has affected humans both socially and economically. Infection from SAR CoV 2 causes not only respiratory disease but also affects several other major organs such as the brain and nervous system. The minor anomaly to the nervous system results in loss of taste and smell function, but occasionally major anomaly like encephalitis also occurs. Encephalitis is essentially the inflammation of the brain tissue, which results in altered brain function, and even death. Management is unfortunately supportive, and the prognosis is generally poor.

Keywords: Encephalitis; Brain Infection; Covid-19

1. Wu Z and McGoogan JM. “Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention”. The Journal of the American Medical Association13 (2020): 1239-1242.
2. Aiyegbusi OL., et al. “Symptoms, complications and management of long COVID: a review”. Journal of the Royal Society of Medicine9 (2021): 428-442.
3. Panariello A., et al. “Anti-NMDA receptor encephalitis in a psychiatric Covid-19 patient: a case report”. Brain, Behavior, and Immunity 87 (2020): 179.
4. Xiang P X X M., et al. “First case of 2019 novel coronavirus disease with encephalitis”. China Xiv 202003 (2020): 00015.
5. Hooper JE., et al. “A postmortem portrait of the coronavirus disease 2019 (COVID-19) pandemic: A large multi-institutional autopsy survey study”. Archives of Pathology and Laboratory Medicine5 (2021): 529-535.
6. Beyerstedt S., et al. “COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection”. European Journal of Clinical Microbiology and Infectious Diseases (2021): 1-15.
7. Meinhardt J., et al. “Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19”. Nature Neuroscience2 (2021): 168-175.
8. Thwaites RS., et al. “Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19”. Science Immunology57 (2021): eabg9873.
9. Crook H., et al. “Long covid-mechanisms, risk factors, and management”. British Medical Journal (2021): 374.
10. Bridwell R., et al. “Neurologic complications of COVID-19”. The American Journal of Emergency Medicine7 (2020): 1549-e1543.
11. Chakraborty S and Basu A. “Catching hold of COVID-19-related encephalitis by tracking ANGPTL4 signature in blood” (2021).
12. Desforges M., et al. “Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system?” Viruses1 (2020): 14.
13. Haider A., et al. “COVID-19 and the brain: acute encephalitis as a clinical manifestation”. Cureus10 (2020).
14. Maschke M., et al. “Update on neuroimaging in infectious central nervous system disease”. Current Opinion in Neurology4 (2004): 475-480.
15. Markand ON. “EEG in the diagnosis of CNS infections”. Neurological Disease and Therapy 44 (1997): 667-690.
16. Kamal YM., et al. “Cerebrospinal fluid confirmed COVID-19-associated encephalitis treated successfully”. BMJ Case Reports CP9 (2020): e237378.
17. Ghosh R., et al. “SARS-CoV-2-associated acute hemorrhagic, necrotizing encephalitis (AHNE) presenting with cognitive impairment in a 44-year-old woman without comorbidities: a case report”. The American Journal of Case Reports 21 (2020): e925641.
18. Lee W J., et al. “Tocilizumab in autoimmune encephalitis refractory to rituximab: an institutional cohort study”. Neurotherapeutics4 (2016): 824-832.
19. Ghosn L., et al. “Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review”. Cochrane Database of Systematic Reviews 3 (2021).
20. Iro MA., et al. “ImmunoglobuliN in the Treatment of Encephalitis (IgNiTE): protocol for a multicentre randomised controlled trial”. BMJ Open11 (2016): e012356.
21. Nepal G., et al. “Efficacy and safety of rituximab in autoimmune encephalitis: A meta‐analysis”. Acta Neurologica Scandinavica5 (2020): 449-459.
22. ACTIV-3/TICO LY-CoV555 Study Group. “A neutralizing monoclonal antibody for hospitalized patients with Covid-19”. New England Journal of Medicine10 (2021): 905-914.